

58
genes

SNVs, Indels

Find answers in your patient's blood

Targeted liquid biopsy for all advanced solid tumors to support your clinical decisions

TERT promoter

Unusual splicing

Gene
translocations



OncoSELECT™
by OncoDNA

WHY CHOOSE ONCOSELECT®?

OncoSELECT® helps optimize treatment strategies across all advanced solid tumors from just two tubes of blood, and matches patients with **targeted therapy**, **hormone therapy** and **potential clinical trials** to improve your patients' clinical outcomes. Rely on a blood-based biomarker-informed approach to make quick and personalized treatment plans for your patient.

IN WHAT SCENARIOS IS ONCOSELECT® USEFUL?

When your patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT® is the perfect alternative to support your clinical decisions thanks to a **fast** and **minimally invasive** analysis of circulating tumor DNA from a blood sample.

OncoSELECT® is available for **all advanced solid tumors in adults** and recommended for **stage 3 or 4** cancer patients when:

- Patient is receiving chemotherapy in neoadjuvant setting. OncoSELECT® may be used to inform on the **patient's response to treatment**.
- Patient is relapsing under current therapy. OncoSELECT® may be used after a line of treatment to **identify if the patient developed resistant mutations**.
- Patient is wild type for specific genes related to their cancer type based on the analysis of their solid biopsy. OncoSELECT® may be performed before the first line of treatment to **assess the heterogeneity of the disease**.

A **63-year-old man with stage IV prostate cancer (mCRPC), metastasized** to lung, lymph node, bone

OncoSELECT allowed the identification of an **AR V890M** variant which explained the lack of clinical benefit of the previous hormonal therapies. Moreover, the detection of **BRCA2 somatic** and **ATM R3008C** variants led to the prescription of **olaparib** with a complete response, and no relapse was identified for the last 6 months.

A **55-year-old non-smoker male** was diagnosed with metastatic non-small-cell lung carcinoma (NSCLC)

Oncologist requested to perform a liquid biopsy test since the lung needle biopsy obtained was of limited quantity. The patient was progressing under erlotinib and OncoSELECT allowed the detection of **EGFR T790M** variant. The detection of this variant led the oncologist to choose **osimertinib** which resulted in good response without any known relapse so far.

A **43-year-old woman with stage IV breast HR cancer**, with recent relapse


OncoSELECT was performed because no solid biopsy was available for this patient. It allowed the identification of **ESR1 L536Q** and **PIK3CA E545K** mutations. Based on these biomarkers, it was decided to prescribe **alpelisib** in combination with **fulvestrant**, an FDA-approved treatment, to the patient. The patient responded well to the treatment without any relapse in the last 6 months.

GENE PANEL

Whole exons			Hotspots			Genes associated with translocatons			Unusual splicing genes
APC	FBXW7	PIK3CA	AKT1	ESR1	MPL	ALK	ETV5	MET	BRCA1
ARID1A	FGFR2	PTEN	ALK	EZH2	mTOR	BRAF	ETV6	NRG1	BRCA2
ATM	FGFR3	RET	AR	GNA11	NF1	BRCA1	EWSR1	NTRK1	MET
BRCA1	H3F3A	SMAD4	ARAF	GNAQ	NTRK1	BRCA2	FGFR1	NTRK2	
BRCA2	HRAS	SMO	BRAF	GNAS	POLE	CD74	FGFR2	RAF1	
CCND1	KRAS	STK11	CTNNB1	IDH1	PDGFRA	EGFR	FGFR3	RET	
CCNE1	MET	TP53	DDR2	IDH2	ROS1	ETV4	KIT	ROS1	
ERBB2	NRAS	VHL	EGFR	KIT	TERT promoter				
PALB2									

ONCOSELECT® STEP BY STEP

Our teams are at hand to assist you every step of the way – from discussing the relevance of the test for your patient and easing the sample collection to understanding the clinical recommendations listed in the report.



ONCOSELECT[®] REPORT

The OncoSELECT report helps you **flag potential resistance mechanisms** and **optimize treatment strategies**.

Each report:

- Contains the patient's medical information (patient diagnosis, tumor type and stage, blood draw date ...)
- Reveals all actionable variants and their biological and therapeutical classifications according to ACMG/AMP guidelines
- Reveals a patient's receptiveness to targeted therapy or hormonal therapy
- Details all relevant recruiting clinical trials with detailed information on the drug development stage and its clinical benefit for your patient.

The screenshot displays the OncoSHARE interface for a patient case. The top navigation bar includes 'Download report (pdf)' and 'OncoSELECT 11/23/21'. The main content area is divided into several sections:

- MEDICAL INFORMATION:** Patient name (Suzanne Salskovic), Patient case ID, Cancer primary site (Non-small-cell lung cancer), and a link to 'Clinical form & pathology'.
- DRUGS:** A table showing drug status: Approved (6 green, 1 orange, 0 red, 0 grey), Approved for other tumor types (0 green, 0 orange, 0 red, 0 grey), and In development (0 green, 0 orange, 0 red, 0 grey).
- COMPREHENSIVE SUMMARY:** Text describing an EGFR L858R variant, its prevalence in NSCLC, and its association with increased cancer cell invasive ability and MPE formation. Includes a link to 'Full comprehensive summary'.
- VARIANTS DETECTION:** A summary showing 1 Pathogenic variant, 0 Likely Pathogenic variants, and 0 Variants of Uncertain Significance (VUS).
- CLINICAL TRIALS:** A table showing 0 clinical trials and 0 clinical trials in Ukraine.
- BIBLIOGRAPHY (2):** A list of references, including 'EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway' by Tsai MF, Chang TH, Wu SG, ... (2015 Sep 4).

Contact us to discuss your patient case



OncoDNA-BioSequence

spain_support@oncodna.com +34 96 071 91 34